August 13, 2020 — Cell therapy clinical trials typically generate a significant quantity and diversity of biologic data intended to characterize disease and patient biology, as well as data intended to demonstrate evidence of therapeutic mechanisms. QuartzBio’s Cliff Culver et al., explores the benefits of capturing and integrating molecular biomarker data within clinical trials to build foundations for data assets. Read the article in the latest issue of Applied Clinical Trials Magazine.
Click here to view the article
Author: Cliff Culver | Senior Vice President | QuartzBio, part of Precision for Medicine
